Sun Pharma target price has been adjusted by Nomura. Discover the implications of this change on the stock's performance.
Read MoreNATCO Pharma Rights Issue: Smart Move for Investors
NATCO Pharma rights issue offers a clear opportunity for investors looking to capitalize on the recent ₹1,279.36 crore approval.
Read More